In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICDs (implantable cardioverter defibrillators) coverage: Medicare extends comment period:

This article was originally published in Clinica

Executive Summary

Medicare's administrators have extended the public comment period on the health plan's coverage policy for implantable cardioverter defibrillators from June 23 to July 23, the Centers for Medicare & Medicaid Services (CMS) has announced. The additional time will give manufacturers and hospitals time to comment on three new questions recently posed by the agency: What is the evidence surrounding the necessity of threshold testing at the time of implantation? What is the evidence of benefits and risks of adding anti-tachycardia pacing to the function of an implantable defibrillator, including the risk of an additional lead? And finally, is there sufficient scientific justification for the development of an ICD patient registry to collect information to better identify predictors of ICD firing for ventricular fibrillation (as a proxy for sudden cardiac death)?

You may also be interested in...



3D Carbon Partners With Resolution Medical To Produce More Than 1 Million Nasal Swabs A Week

Resolution Medical teamed up with Carbon to introduce more than one million 3D-printed nasal swabs a week to address the shortage for COVID-19 testing.

ACC 2020: Medtronic’s Evolut TAVR Works In Low-Risk Bicuspid Study

Early results from the Low-Risk Bicuspid study of the Evolut transcatheter aortic valve replacement system showed low rates of all-cause mortality or stroke.

COVID-19 Will Spur Decentralized and Hybrid Trials – Novartis Hails Digital Investment

The reality is that many trials requiring hospital based tests and interventions cannot be replaced, but crisis will spur take up where practical.

Topics

UsernamePublicRestriction

Register

MT058941

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel